Telefonica willing to use M&A to challenge America Movil in Mexico • 2:52 PM
"We are very open minded to consolidation in Mexico," says Telefonica (TEF +1.3%) COO Jose Maria Alvarez-Pallete. He qualifies his remarks by saying consolidation "might happen not just in terms of merging, but also roaming or network sharing."
Telefonica only has 20% of the Mexican mobile market; market leader America Movil (AMX +1.8%) claims a 70% share. But the recent passage of a telecom reform bill could make it easier for the company to take share from AMX.
The remarks come as Telefonica both makes asset sales in various markets in an effort to pare its debt load, and attempts to acquire KPN's German unit for €8.1B in cash and stock.
If Telefonica tries to expand in Mexico via M&A, it could make a play for NII Holdings' (NIHD -3.1%) Mexican ops. As it is, the carriers have a roaming deal in place.
New Follow our top articles @SAlphaTrending on Twitter
We need to force top managements to hire more sales force and to fund this by cutting their salaries to $0 for one year. they are making a lot of money 850mil,540mil......and millions in option.
we need to be organized and force the board of director to make it happen. we don't have much time to waste.
I am sure they thought and talked about with their lawyers and they took the course.. We don't know better than them...end of point.
RESISTANCE ABOVE +14.8% at 2.25 ± 0.13, type Single, strength 8
+162% at 5.14 ± 0.3, type Triple+, strength 10
+199% at 5.87 ± 0.34, type Double, strength 5
+235% at 6.57 ± 0.38, type Triple+, strength 10 +265% at 7.15 ± 0.41, type Triple+, strength 10
I think will go up regardless the FDA decision....it worth more than $6 without Anchor....and hopefully we get any small positive news on 12/20 and the stock will be over $8.
The FDA will approve it......Vascepa is better than most Statin because the side effect associate with statin.
I agree, and they do about 35-45% of sales off label for Trig between 200 and 500 .. so they increase their LDL and the doctors still prescribe it for patient...which it mean increase their CVD and event...Vascepa should take all Lovaza market share with the proper sales force or a partner.
and the FDA should not allowed doctors to prescribes Lovaza to patents.
but you never see them on yahoo news or other media.
Updated - November 8, 2013 8:05 AM EST)
Citi upgraded Amarin Corporation (NASDAQ: AMRN) from Neutral to Buy with a price target of $2.50 (unchanged). Analyst Jonathan Eckard thinks the company is facing an uphill battle with the FDA, but in his view, the stock's current valuation doesn't reflect opportunity in smaller Marine population. He also sees upside from further cost cutting
he is something....if they stop Reduce-it, he will say that the worse decision they made.....there is no win with this gay....bash all the way.. the stock at $ 1.40 and he still bashing.
so what is your purpose of posting go some where else...you shorting or paid basher.
there is a lot of a new investors buying in, retails and institutions.....where you think all these millions of shares went?